Company: RGNT
Filing Date: 2025-03-11
Form Type: F-1
Source: 0001213900-25-022350
Chunk: 295

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-03-11
Form: F-1
Chunk 295
---
 carrying values of the preferred shares to the deemed liquidation values of such shares since a liquidation event
was not probable of occurring.

<div align='center'>F-41</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 11:- | SHAREHOLDERS’ DEFICIT |

:

Ordinary shares confer to holders the
right to receive notice to participate and vote in the general meetings of the Company and the right to receive dividends if declared.
However, certain ordinary shareholders, who received those shares upon their exercise of options pursuant to the Company’s share
option plan, have signed an irrevocable proxy appointing the Chairman of the Company’s Board of Directors to use the voting rights
of their ordinary shares.

In December 2023, the Company and certain
preferred shareholders signed a voting agreement according to which all issued and outstanding preferred shares shall vote at any shareholders
meeting in order to convert all preferred shares into ordinary shares of the Company effective upon the occurrence of a merger of the
Company with OceanTech. (refer to Note 14).

:

As of December 31, 2023, and 2022, there
are total of 31,716 options outstanding to purchase its ordinary shares, at an exercise price of $9.933. 16,716 options were granted
to Company’s service providers and 15,000 options were granted to Company’s director. The outstanding options were granted
in prior years and are fully vested with no future compensation expenses to be recognized. These options will expire in December 2029.

During the years ended December 31, 2023,
and 2022, the Company didn’t grant additional options and there were no exercise nor forfeiture of options.

As of December 31, 2023, and 2022, all
options are exercisable and have an exercise price of $9.933.

<div align='center'>F-42</div>

REGENTIS BIOMATERIALS LTD.

NOTES TO FINANCIAL STATEMENTS

U.S. dollars in thousands, except share and per share data

| NOTE 11:- | SHAREHOLDERS’ DEFICIT (Cont.) |

As part of the receipt of a short-term
loan (refer to Note 5), the Company issued to the lenders 11,965 warrants which will be exercisable into ordinary shares at an exercise
price of